Genentech Chided for Poor Building Conditions

Drug GMP Report
Roche subsidiary Genentech received a Form 483 from the FDA after an inspection found parts of the processing area for making active pharmaceutical ingredients (APIs) was covered with what resembled rust.

To View This Article:


Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $135.00